COO Cooper Companies Inc.

CooperCompanies Appoints Mark Drury as New Vice President, General Counsel and Corporate Secretary and Announces Randal L. Golden to Retire

CooperCompanies Appoints Mark Drury as New Vice President, General Counsel and Corporate Secretary and Announces Randal L. Golden to Retire

SAN RAMON, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced that Mark Drury has been appointed Vice President, General Counsel and Corporate Secretary effective February 15, 2020, reporting to Albert G. White, President and Chief Executive Officer. Mr. Drury joined CooperCompanies in January of 2011 and is currently the company’s Deputy General Counsel with responsibility for CooperVision’s global legal function along with certain corporate matters. Mr. Drury succeeds Randal L. Golden who announced his plans to retire after many successful years with the company. As part of a smooth transition, Randy will continue to serve in a legal advisory role until February 1, 2021.

“I am very pleased to have Mark join our executive team,” said Mr. White. “Mark has a proven track record of success and his strong leadership skills will ensure our Legal Department remains well positioned to support the organization’s growth into the future.”

“On behalf of CooperCompanies, I want to thank Randy for his years of dedicated service,” continued Mr. White. “Randy was instrumental in building CooperCompanies’ legal function and we greatly appreciate everything he has done and wish him the very best in retirement.”

Prior to joining CooperCompanies, Mr. Drury was an attorney with Latham & Watkins after completing both his MBA and JD from the University of California at Berkeley. Mr. Drury lives with his family in the San Francisco Bay Area and will continue to be based at the corporate headquarters in San Ramon, California.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663

EN
07/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Cooper Companies Inc: 3 directors

A director at Cooper Companies Inc bought 2,000 shares at 82.500USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

CooperCompanies Announces New Chair of the Board and Strategic Review

CooperCompanies Announces New Chair of the Board and Strategic Review SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value. “Bob’s vision, industry knowledge, ...

 PRESS RELEASE

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GA...

 PRESS RELEASE

CooperCompanies Announces Release Date for Fourth Quarter and Full Yea...

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025 SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay c...

 PRESS RELEASE

CooperCompanies Announces Expanded Share Repurchase Program

CooperCompanies Announces Expanded Share Repurchase Program SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch